Correspondence 0001193125-22-302735 from Cue Biopharma, Inc. (CUE)
Cue Biopharma, Inc.
Date: Dec. 12, 2022 · CIK: 0001645460 · Accession: 0001193125-22-302735
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-268687
Letter
Re: Cue Biopharma, Inc.
December 12, 2022
VIA EDGAR SUBMISSION
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, DC 20549
Attention: Doris Stacey Gama
Registration Statement on Form S-3
File No. 333-268687
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Cue Biopharma, Inc. hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-268687), so that it may become effective at 4:00 p.m., Eastern Time, on December 14, 2022, or as soon as practicable thereafter.
Very truly yours,
CUE BIOPHARMA, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP December 12, 2022 VIA EDGAR SUBMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Attention: Doris Stacey Gama Re: Cue Biopharma, Inc. Registration Statement on Form S-3 File No. 333-268687 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Cue Biopharma, Inc. hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-268687), so that it may become effective at 4:00 p.m., Eastern Time, on December 14, 2022, or as soon as practicable thereafter. Very truly yours, CUE BIOPHARMA, INC. By: /s/ Kerri-Ann Millar Name: Kerri-Ann Millar Title: Chief Financial Officer